Skip to Main Content

Advertisement intended for health care professionals

Skip Nav Destination

Simon Harrison: Early Data on AMG 701 for Heavily Pretreated Relapsed/Refractory Multiple Myeloma

December 30, 2021

Simon Harrison, MBBS, PhD, shares results from a phase I first-in-human trial evaluating AMG 701, an anti‑BCMA BiTE® molecule, in patients with heavily pre‑treated relapsed/refractory multiple myeloma.

Advertisement intended for health care professionals

Connect with us:

CURRENT ISSUE
November 2024

Advertisement intended for health care professionals

Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals